FIELD: biotechnology, immunology, virology.
SUBSTANCE: The invention relates to the field of biotechnology, immunology and virology, in particular to an immunobiological agent for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. Also, a method is disclosed for inducing specific immunity to the SARS-CoV-2 virus, comprising administering one or more immunobiological agents to the mammalian body for the prevention of diseases caused by the severe respiratory syndrome virus SARS-CoV-2. The invention allows to effectively induce an immune response against SARS-CoV-2 virus.
EFFECT: the invention allows to effectively induce an immune response against SARS-CoV-2 virus.
10 cl, 5 dwg, 12 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN | 2021 |
|
RU2761904C1 |
IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) | 2021 |
|
RU2743962C1 |
PHARMACEUTICAL AGENT AND METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731342C1 |
USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION (VERSIONS) | 2021 |
|
RU2744444C1 |
USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION IN PEOPLE OVER 60 AND/OR WITH CHRONIC DISEASES (VERSIONS) | 2021 |
|
RU2744442C1 |
EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 19 SEROTYPE AND METHOD OF ITS APPLICATION | 2023 |
|
RU2811791C1 |
IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST SARS-COV-2 AND METHOD FOR USING IT (VERSIONS) | 2021 |
|
RU2765729C1 |
Authors
Dates
2020-05-12—Published
2020-04-23—Filed